Electrical Vestibular Nerve Stimulation (VeNS) As a Treatment for Depression
NCT06051864 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62
Last updated 2024-12-20
Summary
Trial title: Effectiveness of Electrical Vestibular Nerve Stimulation in the Management of Depression
The aim of this study: To better evaluate the efficacy of non-invasive electrical vestibular nerve stimulation (VeNS) as a method of treating Depression, as compared to a sham control.
Allocation: Randomized to either active device or control device usage.
Endpoint classification: Efficacy Study Intervention Model: Parallel Assignment in 1:1 active to control allocation
Sample size: The aim is to recruit a total of up to 60 participants. The study will last 12 weeks in total for each subject.
Conditions
Interventions
- DEVICE
-
Modius Mood Active Device
Battery powered non-invasive neurostimulation device
- DEVICE
-
Sham Device
Placebo comparator sham device (no active stimulation)
Sponsors & Collaborators
-
NRI Institute of Medical Sciences
collaborator UNKNOWN -
Neurovalens Ltd.
lead INDUSTRY
Principal Investigators
-
Sai Sailesh Kumar Goothy · NRI Institute of Medical Sciences
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-12-03
- Primary Completion
- 2024-11-05
- Completion
- 2024-11-05
Countries
- India
Study Locations
More Related Trials
-
Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression
NCT03756129 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
NCT06570369 ·Status: RECRUITING ·Phase: PHASE1
-
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
NCT03887624 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 ·Status: COMPLETED ·Phase: PHASE2
-
An EEG Study of Intravenous Ketamine for Major Depression Disorder
NCT05506462 ·Status: UNKNOWN ·Phase: PHASE4
-
This is a Study to Determine the Antidepressant Effects of AZD6765
NCT00986479 ·Status: COMPLETED ·Phase: PHASE2
-
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
NCT05768126 ·Status: RECRUITING ·Phase: PHASE4
-
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
NCT05414422 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
NCT02417064 ·Status: COMPLETED ·Phase: PHASE3
-
Randomised Controlled Trial of Electroconvulsive Therapy (ECT) in Relapse Prevention of Depression
NCT00627887 ·Status: COMPLETED ·Phase: PHASE4
-
Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder
NCT02659085 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624 ·Status: RECRUITING ·Phase: PHASE3
-
A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder
NCT02724735 ·Status: UNKNOWN
-
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression
NCT01814085 ·Status: COMPLETED ·Phase: PHASE4
-
Apimostinel + Automated Neurocognitive Training for Depression
NCT06400121 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder
NCT02288325 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Assessment of Cost-effectiveness and Side-effects of Depressive Patients Treated With ECT or TCA
NCT05306184 ·Status: ACTIVE_NOT_RECRUITING
-
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
NCT01034462 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
NCT01377194 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
NCT05454410 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Participants With Major Depression
NCT00420004 ·Status: COMPLETED ·Phase: PHASE2
-
Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy
NCT00150839 ·Status: COMPLETED ·Phase: PHASE4
-
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335 ·Status: RECRUITING ·Phase: PHASE1
-
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021 ·Status: RECRUITING ·Phase: PHASE3